Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone

Published:2017-02-22 Issue:5 Volume:19 Page:721-728
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Terra Steven G.¹^ORCID,Focht Kristen²,Davies Melanie³^ORCID,Frias Juan⁴,Derosa Giuseppe⁵^ORCID,Darekar Amanda⁶,Golm Gregory⁷,Johnson Jeremy⁷,Saur Didier⁸,Lauring Brett⁷,Dagogo-Jack Sam⁹

Affiliation:

1. Pfizer; Andover Massachusetts

2. Pfizer; Collegeville Pennsylvania

3. Diabetes Research Centre; University of Leicester; Leicester UK

4. National Research Institute; Los Angeles California

5. University of Pavia and IRCCS Policlinico San Matteo Foundation; Pavia Italy

6. Pfizer Ltd; Tadworth UK

7. Merck & Co., Inc.; Kenilworth New Jersey

8. Pfizer; Paris France

9. University of Tennessee Health Sciences Center; Memphis Tennessee

Funder

VERTIS MONO trial

Funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and Pfizer Inc

European Association for the Study of Diabetes

Janssen Pharmaceuticals

Eli Lilly and Company

AstraZeneca

Sanofi

AbbVie

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12888/fullpdf

Reference22 articles.

1. SGLT2 inhibitors: benefit/risk balance;Scheen;Curr Diab Rep,2016

2. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects;Ferrannini;Nat Rev Endocrinol,2012

3. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors;Mascitti;J Med Chem,2011

4. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin;Amin;Diabetes Obes Metab,2015

5. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension;Amin;Diabetes Obes Metab,2015

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial;Diabetes, Obesity and Metabolism;2024-07-26

2. Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus;Medicinal Chemistry Research;2024-07-10

3. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

4. Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus;Journal of Diabetes Investigation;2024-03-08

5. An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?;The Journal of Clinical Pharmacology;2024-01-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3